THYmine 2

Full title: An observational study to assess the ability of the thymine loading test to prospectively categorise patients with gastrointestinal or breast cancer who cannot tolerate fluoropyrimidine treatment
Cancer type: Gastrointestinal and Breast
Status: In follow up

Brief description:

 

This study builds upon the first THYMINE Study. The primary objective is to assess the ability of the thymine loading test to prospectively categorise patients who cannot tolerate fluoropyrimidine treatment, in a wider patient cohort. Our second objective is to compare the thymine test to the predictive ability of a panel of known deleterious SNP in the DPYD gene. Thirdly we will look at using freshly collected buccal mucosal cells to assess inter-individual differences in 5-FU transmembrane uptake, and determine if high uptake is also associates with risk of 5-FU toxicity.
Sites: Auckland City Hospital, Tauranga, Dunedin, Canopy Cancer Care (Auckland), Christchurch
Lead Investigator: Associate Professor Nuala Helsby
Contact: Eibhlin Corrigan (eibhlin.corrigan@auckland.ac.nz)
Sponsor: University of Auckland
Funder: Health Research Council of New Zealand, Gut Cancer Foundation
ClinicalTrials.gov reference: ACTRN12617001109392 (click for more details)
Ethics number: 17/CEN/149
Publications: Helsby N, Burns K, Findlay M, Porter D, Strother M. Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients. New Zealand Medical Journal. 2021;134(1545):106-114